Cramer's 'Mad Money' Recap: Look to Housing and Insurance

Tickers in this article: AIG ANR BIIB EXC GLD HD IVR LL LOW NLY OC PFE PIR QCOR REGN SHW TRV VMC WHR WY
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener .

NEW YORK ( TheStreet) -- Housing and insurance are two more themes that will be working in 2013, Jim Cramer told "Mad Money" viewers Tuesday in the next installment in his weeklong series on what investors should be buying on any Washington-induced market weakness.

Cramer said the housing market remains huge, and any company that sells into it should be yielding big returns in 2013. Of course that means the home builders, but they've already run a lot, said Cramer, which is why he'd look into the building-materials and home-furnishing companies.

Everything from Pier 1 Imports (PIR) to Owens Corning (OC) to Whirlpool (WHR) to Sherwin Williams (SHW) should be participating in the housing recovery, said Cramer.

That also means stocks like Weyerhaeuser (WY) , a stock Cramer owns for his charitable trust, Action Alerts PLUS, and Vulcan Materials (VMC) as well.

Cramer's next big theme for 2013: insurance. Yes, it's boring, he said, but given how beaten down this sector has been, there will be only upside as all of their beleaguered investments finally start bearing fruit. Cramer said he's a fan of Travellers (TRV) , along with American International Group (AIG) , another Action Alerts PLUS name.

Executive Decision

In the "Executive Decision" segment, Cramer spoke with Dr. Leonard Schleifer, president and CEO of Regeneron Pharmaceuticals (REGN) , one of the many companies presenting at the annual JPMorgan Chase (JPM) health-care conference this week.

Schleifer said Regeneron is celebrating its 25th anniversary this year and has always been based on doing good science that focuses on what patients need. That's why the company is working is many different areas from cholesterol to eye care.

When asked about the perceived weakness in the quarterly results, Schleifer said some analysts were expecting strong sales after a competitor ran into a formulation problem with a competing drug, but that scenario never materialized. He said Regeneron continues to grow at 50% a year and is expecting to have a phenomenal 2013.

When asked whether his company's new cholesterol-lowering drugs could become bigger than its current Eylea eye-care treatment, Schleifer said he believes that it can. He said REGN72 is a totally new class of cholesterol drug and one that's showing a lot of promise in lowering levels by 60% to 70% with few side effects.

Cramer said Regeneron remains one of his favorite biotech stocks.

Off the Charts

In the "Off The Charts" segment, Cramer went head to head with colleague Tim Collins over the chart of Pfizer (PFE) , a boring Big Pharma name that might just be getting a little more exciting in 2013.

According to Collins' research, the daily chart of Pfizer is displaying the bullish reverse head-and-shoulders pattern, with the left shoulder in October, the head in November and the right shoulder in December. Collins said based on this pattern, Pfizer could see a 6% move in the short term and more over the next six months. This trend was confirmed by the TRIX momentum indicator.

Usage of this site is governed by TheStreet's Terms of Use available here. Information collected on this site may be collected by TheStreet and OC Register. TheStreet's use of information collected on this site will be governed by TheStreet's privacy policy available here. OC Register's use of information collected on this site will be governed by OC Register's privacy policy available here. If either TheStreet's or OC Register's privacy policy have provisions that are more restrictive than the provisions of the other party's privacy policy, such more restrictive provisions shall not apply to such other party.

Copyright © 2012 Orange County Register Communications. All Rights Reserved.
Site Help | Site Map